Meeting Highlights From the 2011 Breast Cancer Symposium
Present-day science for future therapies
October 10, 2011|The Journal of Community and Supportive Oncology
Author and Disclosure Information
“Most notably, there was a statistically significant interaction between the H/I biomarker and treatment (P = 0.02), indicating that the magnitude of letrozole benefit depends on the expression level of H/I,” he said. “These results suggest that patients with tumors expressing high H/I will benefit from extended endocrine therapy.”
Dr. Sgroi reported receiving research funding from bioTheranostics Inc. The study was supported in part by Novartis, the manufacturer of letrozole.
